MGI boost for Eisai, but lansoprazole languishes
This article was originally published in Scrip
Eisaiwas keen to stress at its first quarter results briefing the positive effect that its acquisition of MGI Pharma was already having, pointing out that the move had already boosted sales of oncology products to 10% of the consolidated total in the first quarter, compared with less than 2% last year.
You may also be interested in...
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.